Pfizer Inc.

Pfizer Inc.

PFE

$30.79

Updated: 05/11/2026, 00:14:06

Market Cap
$175.49B
Sector
Healthcare
Industry
Drug Manufacturers - General
Country
US

No historical data available

Company Profile

Pfizer Inc. is a global biopharmaceutical leader engaged in the research, development, production, marketing, and distribution of a wide array of medicinal and vaccine products worldwide. Its comprehensive portfolio addresses diverse therapeutic areas, including cardiovascular health and women's health, featuring key brands such as the Premarin family and Eliquis. The company also offers advanced biologics, small molecule drugs, immunotherapies, and biosimilars for various conditions, exemplified by Ibrance, Xtandi, and Retacrit. Furthermore, Pfizer provides sterile injectables, anti-infective agents, and a significant oral treatment for COVID-19, including Paxlovid. A substantial portion of its offerings comprises vaccines for infectious diseases such as pneumococcal and meningococcal disease, tick-borne encephalitis, and COVID-19, with notable products like Comirnaty and the Prevnar family. The firm also develops biosimilars for chronic autoimmune and inflammatory disorders, including Inflectra and Xeljanz, alongside specialized therapies for rare conditions like amyloidosis, hemophilia, and endocrine disorders, under brands such as Vyndaqel and BeneFIX. Beyond its proprietary products, Pfizer operates a contract manufacturing division. Its extensive customer base includes wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual medical practices, and public health organizations. The company actively fosters strategic collaborations with numerous partners, such as Bristol-Myers Squibb Company, BioNTech SE, and Merck KGaA. Established in 1849, Pfizer Inc. is headquartered in New York, New York.

USD
NYSE
CEO: Albert Bourla
Employees: 75,000
https://www.pfizer.com
Asset Summaries
Latest generated summaries for PFE

No summaries found.

Detailed business
Evidence-backed facts extracted from the latest official annual filing.
PFE-10-k-fy2025.html5.0 MBtext/htmlENFiled 26/02/2026Period ended 31/12/2025

Business monitoring

Reported and calculated KPIs plus operational exposure disclosed in the FY 2025 filing.

Evidence-backed · 34 KPI observations

Revenue

N/A

FY — · Reported

Net income

$7.8B

FY 2025 · Reported

Gross margin

N/A

FY — · Reported

Free cash flow

$9.1B

FY 2025 · Calculated

R&D intensity

N/A

FY — · Reported

Share repurchases

N/A

FY — · Reported

Earnings and cash generation
USD billions, directly sourced from inline XBRL; free cash flow is operating cash flow less capex.
Profitability and reinvestment
Margins and R&D as a percentage of revenue.
Top products and services
Reported sales by product or service. Shares and growth are calculated from the filing values.
Product / serviceSalesShare of salesYoY growthBy reported area
products_over_1b_usd
Source evidence
“We recorded revenues of more than $1 billion for each of 12 products that collectively accounted for 65% of Total revenues in 2025. For example, Eliquis accounted for 13% of Total revenues in 2025.”
12N/AN/ANot disclosed by product and area

Other offerings mentioned without separate sales

Key disclosed products
Oncology portfolio
Specialty Care portfolio
Primary Care portfolio
Hospital and Biosimilars portfolio

Area-level product sales are displayed only when the filing reports a product × geography breakdown. Regional totals are not allocated across products by estimation.

Geographic footprint
What the filing identifies, separated by location role so partner manufacturing is not presented as Apple-owned factories.
1 named headquarters
0 manufacturing countries
0 individually named factories

Map layer

Pins show disclosed operations. The heatmap colors the filing’s reported geographies; regional figures shade the region and are not estimates for each country.

No reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosure
Named headquarters Manufacturing partner country

Only locations and quantities explicitly supported by the filing are displayed. A country-level manufacturing percentage or product allocation is shown only when the source discloses it; materiality scores are never presented as production shares.

How the business makes money

Company overview

Research-based global biopharmaceutical company (Pfizer Inc.)

98%
Source evidence
“Pfizer Inc. is a research-based, global biopharmaceutical company.”

Company overview

Research-based global biopharmaceutical company (incorporated Delaware, June 2, 1942)

98%
Source evidence
“Pfizer Inc. is a research-based, global biopharmaceutical company.”

Operating segments 2025

Three operating segments in 2025: Biopharma (only reportable), PC1, Pfizer Ignite; new Global Hospital and Biosimilars organization effective Jan 1, 2026

97%
Source evidence
“In 2025, we managed our commercial operations through a global structure consisting of three operating segments: Biopharma, PC1 and Pfizer Ignite. Biopharma was the only reportable segment.”

Operating segments

Three operating segments: Biopharma (only reportable segment), PC1 (CDMO/specialty API supplier), Pfizer Ignite (being wound down)

97%
Source evidence
“We manage our commercial operations through a global structure consisting of three operating segments, each led by a single manager: Biopharma, PC1 and Pfizer Ignite.”

Restructuring cost drivers across functions

Cost-reduction/productivity initiatives involve site closings, workforce reductions, shared services expansion and digital enablement, impacting sales/marketing, manufacturing, R&D and corporate enabling functions.

85%
Source evidence
“we typically incur costs and charges for site closings and other facility rationalization actions, workforce reductions and the expansion of shared services, including the development of global systems, and digital enablement”

Key disclosed products

Comirnaty, Paxlovid, Vyndaqel family, Eliquis, Padcev, Lorbrena, Abrysvo, Enbrel, oncology biosimilars

95%
Source evidence
“The operational decrease was primarily driven by declines in COVID-19 product revenues, partially offset by increases from the Vyndaqel family, Eliquis, Padcev, Lorbrena, Abrysvo and Oncology biosimilars.”

Oncology portfolio

Innovative oncology portfolio of ADCs, small molecules, bispecifics and immunotherapies (Ibrance, Xtandi, Padcev, Adcetris, etc.)

95%
Source evidence
“Innovative oncology product portfolio of ADCs, small molecules, bispecifics and other immunotherapies that treat a wide range of cancers”

Specialty Care portfolio

Inflammation & immunology, rare disease (amyloidosis, hemophilia, endocrine), anti-infective and immunoglobulin medicines

95%
Source evidence
“Rare disease product portfolio for a number of therapeutic areas with rare diseases, including amyloidosis, hemophilia and endocrine diseases – select products include: the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla and Hympavzi.”

Primary Care portfolio

Internal medicine (Eliquis), migraine (Nurtec ODT/Vydura, Zavzpret), vaccines (Prevnar family, Comirnaty, Abrysvo, FSME/IMMUN-TicoVac, Nimenrix, Trumenba), COVID-19 treatment (Paxlovid)

95%
Source evidence
“Vaccines product portfolio across all ages – select products include: the Prevnar family, Comirnaty, Abrysvo, FSME/IMMUN-TicoVac, Nimenrix and Trumenba.”

Hospital and Biosimilars portfolio

Off-patent branded and generic sterile injectables and biosimilars (new Global Hospital and Biosimilars organization effective January 1, 2026)

93%
Source evidence
“at the beginning of 2026, we made changes in our commercial structure, which included the transition of certain off-patent branded and generic sterile injectables and biosimilars... to a new Global Hospital and Biosimilars organization”

2025 revenue drivers

Revenues decreased $1.0B (2%) to $62.6B, driven by COVID-19 declines; excluding Comirnaty and Paxlovid, revenues +6% operationally

96%
Source evidence
“Excluding contributions from Comirnaty and Paxlovid, Total revenues increased 6% operationally.”

Product concentration — 12 products >$1B, 65% of revenue

12 products each >$1B accounted for 65% of Total revenues in 2025; Eliquis alone 13%

95%
Source evidence
“We recorded revenues of more than $1 billion for each of 12 products that collectively accounted for 65% of Total revenues in 2025. For example, Eliquis accounted for 13% of Total revenues in 2025.”

Operations and dependencies

Raw materials sourcing

Raw materials procured worldwide from numerous suppliers; no significant 2026 availability impact anticipated but supply chain risks monitored

93%
Source evidence
“We do not anticipate the availability of raw materials to have a significant impact on our operations in 2026, but are monitoring potential supply chain disruptions as a result of ongoing geopolitical and trade negotiations”

Positioning and strategy

Metsera acquisition (obesity)

Acquired Metsera in November 2025 (obesity/cardiometabolic); also in-licensing agreements with YaoPharma and 3SBio in 2025

93%
Source evidence
“our acquisitions of Metsera in November 2025 and Seagen in December 2023 and our in-licensing agreements with YaoPharma and 3SBio entered into in 2025 in the obesity and cardiometabolic diseases and oncology therapeutic areas”

Seagen acquisition (oncology)

Acquired Seagen in December 2023 (oncology)

93%
Source evidence
“our acquisitions of Metsera in November 2025 and Seagen in December 2023”

Business development: Seagen and Metsera

Recent business development initiatives include acquisitions of Seagen and Metsera

92%
Source evidence
“See Note 2 for a discussion of our recent business development initiatives, including the acquisitions of Seagen and Metsera”

Managed care / PBM pricing pressure

MCO consolidation and PBM scrutiny increase downward pricing pressure; branded products increasingly placed on higher tiers/non-preferred status

93%
Source evidence
“Since MCOs purport to seek to contain and reduce healthcare expenditures, their growing influence has increased downward pressure on drug prices, as well as negatively impacted revenues.”

R&D pipeline and therapeutic areas

R&D focused on oncology, internal medicine, vaccines, I&I; ~$500M of 2025 cost-realignment savings to be reinvested in R&D in 2026

92%
Source evidence
“approximately $500 million of R&D savings achieved from our ongoing realigning our cost base program in 2025 is expected to be reinvested in R&D programs in 2026”

2026 key priorities

2026 priorities: (1) Maximize value of key transactions; (2) Deliver on critical R&D milestones; (3) Invest to maximize post-2028 growth; (4) Scale AI across our business

96%
Source evidence
“Our 2026 key priorities are: 1.Maximize value of key transactions 2.Deliver on critical R&D milestones 3.Invest to maximize post-2028 growth 4.Scale AI across our business.”

Cost realignment and manufacturing optimization programs

Enterprise-wide cost realignment program (expanded 2025, AI/digital-driven SI&A savings) and multi-year Manufacturing Optimization Program (launched Q2 2024)

95%
Source evidence
“In the second quarter of 2024, we announced that we launched a multi-year, multi-phased program to reduce our costs of goods sold”

Risks, financing, and outlook

September 2025 U.S. Government agreement

Sept 2025 agreement with Trump Administration: MFN-style pricing, TrumpRx.gov discounts up to 85% (avg 50%), 3-year Section 232 tariff grace period tied to U.S. manufacturing investment

97%
Source evidence
“The September 2025 agreement also provides a three-year grace period during which time our products will not face Section 232 tariffs, provided the Company further invests in manufacturing in the U.S.”

EU pharmaceutical legislative initiatives

Several recently adopted or proposed EU legislative initiatives may affect the business, including the EU Pharma Package, EU HTA-R, EU Critical Medicines Act, EU Biotech Act, EU AI Act, EU Data Act, and EU Health Data Space Regulation.

95%
Source evidence
“the EU Pharma Package, the EU HTA -R, the EU Critical Medicines Act, and the EU Biotech Act, as well as legislation such as the EU AI Act, EU Data Act, and the EU Health Data Space Regulation”

Cost-reduction and restructuring execution risk

Enterprise-wide cost realignment program and manufacturing optimization program may fail to deliver projected benefits; restructurings risk loss of continuity, key employees, and pipeline delays.

95%
Source evidence
“our ability to realize the projected benefits of our cost-reduction and productivity initiatives, including our enterprise-wide cost realignment program and manufacturing optimization program”

Intangible assets, goodwill and IPR&D impairment risk

Significant intangible assets including IPR&D and goodwill carry impairment/write-off risk from regulatory approvals, competition, loss of market exclusivity, and adverse legal/regulatory events.

95%
Source evidence
“Our consolidated balance sheet contains significant amounts of intangible assets, including IPR&D and goodwill. For IPR&D assets, the risk of failure is significant”

Tax law and regulatory change exposure (IRA, OBBBA, global minimum tax)

Results could be adversely affected by changes in laws including the IRA, the OBBBA (still subject to further guidance), and global minimum taxation requirements effective in most jurisdictions since January 1, 2024.

95%
Source evidence
“the IRA, and the OBBBA, which is still subject to further guidance; the adoption of global minimum taxation requirements outside the U.S. generally effective in most jurisdictions since January 1, 2024”

IP loss and pipeline replenishment risk

Loss/expiration/invalidation of IP rights, patent litigation settlements, and licensing expirations can materially adversely affect revenues

94%
Source evidence
“The loss, expiration or invalidation of intellectual property rights, patent litigation settlements and judgments, and the expiration of co-promotion and licensing rights can have a material adverse effect on our revenues.”

Managed care / PBM pricing pressure

U.S. MCO/PBM consolidation and cost-containment (rebates, formulary exclusion, prior authorization, IRA-driven pressure) may erode pricing and access

93%
Source evidence
“The negotiating power of MCOs, PBMs and other private third-party payors has increased due to consolidation, and they, along with state and federal governments, increasingly employ tools to control costs”

Equity investment and pension plan volatility

Changes in fair value of equity investments increase income volatility; pension and postretirement plans are exposed to investment returns and discount rate changes.

90%
Source evidence
“Our pension and postretirement plans are subject to volatility from changes in the fair value of equity investments and other investment risk in the assets funding these plans, as well as changes in the appropriate discount rates”

Tariff and trade policy exposure

New tariffs or trade/foreign policy changes could materially adversely affect business, earnings, cash flow, liquidity and financial guidance; impacts depend on scope, duration, and retaliatory tariffs.

90%
Source evidence
“issued or future executive orders or other new or changes in laws, regulations or policy regarding tariffs or other trade or foreign policy, could have a material adverse effect on our business, earnings, cash flow, liquidity and financial guidance”

Competition including from China; MFN/Trump Administration pricing agreements

Rising competition including China-based entrants, generic price erosion in China, vaccine discount pressure, and voluntary U.S. pricing agreements with the Trump Administration

90%
Source evidence
“we are facing an increasing number of potential competitors worldwide, including from China, that have expanded R&D capabilities.”

Government cost-cutting and data transfer restrictions

Government cost-cutting measures may impact regulatory review capacity; restrictions on data security, localization and cross-border data transfers could affect operations.

85%
Source evidence
“government cost-cutting measures and related impacts on, among other matters, government staffing, resources and ability to timely review and process regulatory or other submissions; restrictions related to certain data transfers”

Customer demand shift toward sustainability / Net Zero expectations

Ability to compete could be affected by changing customer preferences, such as demand for companies to establish Net Zero targets or offer more sustainable products; perceived failure risks brand damage and reduced demand.

85%
Source evidence
“changing customer preferences and requirements, such as demand for companies to establish Net Zero targets or offer more sustainable products”

Material exposure graph

Eliquis
Revenue Exposure

Eliquis alone accounted for 13% of Total revenues in 2025 among the 12 products >$1B comprising 65% of revenues.

Relevance 90·Dependency 75·Confidence 95
Source evidence
“Eliquis accounted for 13% of Total revenues in 2025.”
Inflation Reduction Act (IRA)
Regulatory Exposure

IRA pricing plus payor consolidation expected to increase pricing pressure as IRA prices become public; payors may seek larger rebates.

Relevance 88·Dependency 80·Confidence 90
Source evidence
“as the IRA prices become publicly available, we may face greater pricing pressure from third-party payors, including insurers and PBMs”
PBMs and managed care organizations
Customer Exposure

U.S. MCO/PBM consolidation and cost-containment tools (rebates, formulary placement, utilization management) directly affect pricing and access for Pfizer products.

Relevance 85·Dependency 75·Confidence 92
Source evidence
“The negotiating power of MCOs, PBMs and other private third-party payors has increased due to consolidation”
Managed Care Organizations and PBMs
Customer Exposure

MCO consolidation and PBM formulary/tiering decisions increase downward pressure on drug prices and negatively impact revenues.

Relevance 85·Dependency 70·Confidence 94
Source evidence
“their growing influence has increased downward pressure on drug prices, as well as negatively impacted revenues.”
Inflation Reduction Act (IRA)
Regulatory Exposure

Changes to the IRA are explicitly cited as a law whose change could adversely affect future results.

Relevance 85·Dependency 70·Confidence 90
Source evidence
“new or changes in accounting standards, tariffs, tax laws and regulations internationally and in the U.S., including, without limitation, the IRA, and the OBBBA”
Section 232 tariffs
Regulatory Exposure

September 2025 U.S. Government agreement provides a three-year grace period from Section 232 tariffs conditional on further U.S. manufacturing investment.

Relevance 85·Dependency 60·Confidence 95
Source evidence
“The September 2025 agreement also provides a three-year grace period during which time our products will not face Section 232 tariffs, provided the Company further invests in manufacturing in the U.S.”
Comirnaty
Revenue Exposure

COVID-19 product revenue declines drove the 2025 revenue decrease; Comirnaty has fall/winter seasonal demand.

Relevance 80·Dependency 65·Confidence 94
Source evidence
“The operational decrease was primarily driven by declines in COVID-19 product revenues”
EU Pharma Package and related EU legislation
Regulatory Exposure

Recently adopted or proposed EU legislative initiatives may affect Pfizer's EU business.

Relevance 80·Dependency 65·Confidence 90
Source evidence
“In the EU, several recently adopted or proposed legislative initiatives may affect our business, including the EU Pharma Package, the EU HTA -R, the EU Critical Medicines Act, and the EU Biotech Act”
Tariffs / trade policy
Geopolitical Exposure

New or changed tariffs and retaliatory actions could materially affect business, earnings, cash flow, liquidity and financial guidance.

Relevance 80·Dependency 60·Confidence 90
Source evidence
“potential retaliatory tariffs or other retaliatory actions imposed by other countries”
Comirnaty and Paxlovid (COVID-19 products)
Revenue Exposure

COVID-19 product revenues have decreased substantially over time and could continue to decrease.

Relevance 78·Dependency 65·Confidence 92
Source evidence
“revenues from Comirnaty and Paxlovid have decreased substantially over time and could continue to decrease.”
Paxlovid
Demand Driver

Paxlovid utilization follows COVID-19 infection trends; revenues fluctuate with timing, duration and severity of infections.

Relevance 75·Dependency 60·Confidence 92
Source evidence
“For Paxlovid, utilization is expected to follow infection trends, and revenues may fluctuate based on the timing, duration and severity of COVID-19 infections.”
Paxlovid
Demand Driver

Paxlovid revenues trend with COVID-19 infection rates.

Relevance 70·Dependency 55·Confidence 93
Source evidence
“In addition, Paxlovid revenues trend with COVID-19 infection rates.”
AI
Technology Dependency

Scaling AI across R&D, manufacturing, commercial and patient engagement is a stated 2026 priority to improve productivity and accelerate innovation.

Relevance 70·Dependency 55·Confidence 93
Source evidence
“In addition, we are scaling AI across R&D, manufacturing, commercial and patient engagement to improve productivity and accelerate innovation.”
Alliance/collaboration partners
Revenue Exposure

Alliance revenues from co-commercialization partners are a disclosed revenue stream with defined accounting treatment.

Relevance 70·Dependency 55·Confidence 85
Source evidence
“Alliance revenues are recorded as we perform co-promotion activities for the collaboration and the collaboration partners sell the products to their customers.”
Global minimum taxation
Cost Driver

Global minimum tax requirements effective since January 1, 2024 outside the U.S. are cited as a potential adverse change to results.

Relevance 65·Dependency 55·Confidence 85
Source evidence
“the adoption of global minimum taxation requirements outside the U.S. generally effective in most jurisdictions since January 1, 2024”
Aging global population
Demand Driver

Aging global population generating increased demand for innovative medicines and vaccines is cited as a long-term growth opportunity.

Relevance 65·Dependency 50·Confidence 90
Source evidence
“an aging global population that is generating increased demand for innovative medicines and vaccines that address patients' unmet needs”
China
Competitive Exposure

Intense generic competition in China has caused and may cause price cuts and volume loss; China-based competitors expanding R&D capabilities.

Relevance 65·Dependency 50·Confidence 90
Source evidence
“In China, we expect to continue to face intense competition by certain generic manufacturers, which has resulted, and may result in the future, in price cuts and volume loss of some of our products.”
Government customers (receivables credit risk)
Customer Exposure

Receivables are pooled by government vs non-government customer type for credit-loss reserves, indicating government payer exposure.

Relevance 60·Dependency 50·Confidence 80
Source evidence
“customer type (high risk versus low risk and government versus non-government)”
Key employee retention during restructurings
Cost Driver

Restructurings may cause loss of key employees and retention issues, affecting operations.

Relevance 60·Dependency 50·Confidence 85
Source evidence
“adverse effects on employee morale, loss of key employees and/or other retention issues during transitional periods”
Supply chain disruption risk
Supplier Dependency

Geopolitical and trade negotiations could disrupt raw material supply and impact costs; mitigation includes supplier management and advanced purchasing.

Relevance 60·Dependency 45·Confidence 90
Source evidence
“We are continuing to monitor and implement mitigation strategies to reduce any potential risk or impact including active supplier management, qualification of additional suppliers and advanced purchasing to the extent possible.”
Sustainability / Net Zero customer expectations
Customer Exposure

Customer preferences for Net Zero targets and sustainable products could affect Pfizer's ability to compete and product demand.

Relevance 55·Dependency 40·Confidence 80
Source evidence
“such as demand for companies to establish Net Zero targets or offer more sustainable products”
U.S. Dollar
Currency Exposure

Foreign exchange rate changes affect reported results; 2025 revenues included $247 million favorable FX impact.

Relevance 55·Dependency 40·Confidence 85
Source evidence
“partially offset by a favorable impact of foreign exchange of $247 million”
Full company information
Latest profile, trading, valuation, and identifier data stored for PFE.
Share price
$30.79
Market cap
$175.49B
Exchange
NYSE
Currency
USD
CEO
Albert Bourla
Employees
75,000
IPO date
01/06/1972
Beta
0.276
Last dividend
$0.00
Day range
$30.04 – $30.90
52-week range
$23.62 – $31.06
1-day performance
2.63%
1-year performance
30.36%
Current drawdown (1Y)
-0.87%
CIK
0000078003
CUSIP
717081103
ISIN
US7170811035
Created
07/12/2025, 05:43:26
Last update
05/11/2026, 00:14:06

Track Pfizer Inc. with an AI analyst

See which prediction-market events move PFE, how its filings map to real-world exposure, and what 12 AI strategies are doing with positions like it.

Free forever to follow AlphaBrain’s AI strategies. No card required.

Latest Database News
News linked to PFE from your Railway `news_articles` table.

This $25 Billion Acquisition Just Unlocked a New Era of Growth for Pfizer — and Why It's a Flawless Safe-Haven for Retirees

24/7 Wall Street • STOCK • 11/06/2026, 16:26:07

A Sizzling 6.7% Dividend Yield? 1 Under-the-Radar Reason I Am Holding Off on Pfizer Stock at $25

24/7 Wall Street • STOCK • 11/06/2026, 16:23:39

Prediction: Pfizer Stock Will Double on This Date

24/7 Wall Street • STOCK • 10/06/2026, 04:06:09

RBC Capital Upgrades Pfizer (NYSE: PFE) Amid Positive Drug Developments

Market Data • Market Data • 10/06/2026, 00:18:39

Amneal and Pfizer GLP-1 Deal: New Growth Lever?

Zacks Investment Research • STOCK • 09/06/2026, 15:20:32

Pfizer Inc. (PFE) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Seeking Alpha • STOCK • 08/06/2026, 13:48:30

Wall Street Breakfast Podcast: Pfizer Chases Monthly Edge

Seeking Alpha • STOCK • 08/06/2026, 09:04:32

US FDA approves Pfizer's bleeding disorder drug for children

Reuters • STOCK • 08/06/2026, 08:49:21

3 Dividend Stocks to Buy Hand Over Fist in June

The Motley Fool • STOCK • 07/06/2026, 03:30:00

Can Pfizer's Dividend Survive the Patent Cliff? This $10.5 Billion Cancer Bet Could Hold the Answer.

The Motley Fool • STOCK • 06/06/2026, 15:32:00

Pfizer's 6.7% Yield Looks Scary -- but the Dividend Story Is Stronger Than It Seems

The Motley Fool • STOCK • 06/06/2026, 14:15:00

Pfizer's monthly obesity shot has side-effect profile similar to Wegovy in midstage trial

Reuters • STOCK • 06/06/2026, 11:06:33